Clicky

Herpes Cure And Treatment

Admedus Herpes Vaccine Phase 2

Admedus Limited (ASX: AHZ) will this month start vaccine dosing under its Herpes Simplex 2 (HSV-2) Phase II study with patient enrolment on track for completion this quarter. The company, now known under the name Admedus Vaccines, is researching DNA technology for vaccines with prophylactic and therapeutic potential. 4 million was posted as funds raised towards Phase II vaccine testing and research.

When Australian biotech Admedus announced Phase I results for its herpes simplex virus vaccine last week, it was far from the first company to do so. But there’s an important difference between this new crop of developers and those that have already struck out on an HSV-2 vaccine, Genocea CEO Chip Clark told FierceVaccines. Since that time several other potential vaccines being tested such as Admedus 2, Vical 3 and HSV-529 4. The vaccines must all go through phase II and phase III trials before being approved by the FDA, a process that typically takes at least 15 years.

Biotechs Angling For T-cell Response In Race For Next-gen Herpes Vaccine

The company had earlier this year received positive interim results for the therapeutic vaccine for Herpes Simplex Virus (HSV-2) Phase I study and is scheduled to release additional data this quarter once confirmatory assays are completed. Admedus’ (ASX: AHZ) final results from its Phase I Herpes Simplex Virus (HSV-2) vaccine study has showed that 95 (19 of 20) of the participants had a positive T-cell response when the trial reached is primary endpoint of safety. Admedus Limited’s Herpes vaccine Phase II study receives ethics approval.

Australia’s Admedus are boasting good results from early clinical trials of their version of the vaccine and Tomegavax, also in the States, is hot on the heals of a discovery with the support of the Bill and Melinda Gates foundation. All of the companies in the race are on phase II of their journeys and things are looking good so far with positive results being reported from all corners. In principle, there is no reason that a safe and effective HSV-2 vaccine could not be deployed in the human population to prevent HSV-2 genital herpes. What do you think about Admedus and Genocea vaccines? UL29, which is defective in HSV DNA replication, has been advanced to a Phase 1 study. Admedus (formally Coridon) to initiate phase II HSV-2 vaccine clinical trial before end 2014. There are (at my last count) 5 vaccine/therazine clinical trials going on. On top of that, Australian biotech Admedus just announced positive early clinical results for its own genital herpes vaccine. Big pharma dabbled in developing a genital herpes vaccine, but GlaxoSmithKline was particularly noteworthy for its epic flop compared to controls, it actually caused even worse outbreaks in the women studied in a huge Phase III study.

Herpes Vaccine Draws Nearer

Australian healthcare group Admedus released results on Thursday of the Phase 1 trial of Professor Frazer’s new vaccine to treat the herpes simplex virus HSV2. ‘We are looking forward to advancing our HSV-2 vaccine into a Phase II clinical study later this year but we will continue advancing our vaccines to treat Human Papillomavirus and cervical cancer. Admedus looking to initiate Phase II study for Herpes simplex virus (HSV-2) therapeutic vaccine by year end. Scientists created the vaccine HSV529 by removing two key proteins from the vaccine virus. In another trial conducted by Admedus, a diversified health company, the reality of a vaccine and a possible cure for the virus may be closer than you think. The initial phase of the clinical trial showed great results, which is leading them down the path of starting Phase 2. Admedus continues to advances the keenly awaited key Phase II HSV-2 study with the company anticipating interim results in the fourth quarter of 2015. Given that there is no cure available for HSV-2, which is a life-long infection, success will allow the company to tackle an unmet medical need with an addressable market estimated at 6 billion. Australian healthcare group Admedus released results last week of the Phase 1 trial of Professor Frazer’s new vaccine to treat the herpes simplex virus HSV2. We are looking forward to advancing our HSV-2 vaccine into a Phase II clinical study later this year but we will continue advancing our vaccines to treat Human Papillomavirus and cervical cancer. Admedus (ASX: AHX) has announced interim study results on its phase 1 trial of a therapeutic vaccine for herpes simplex virus (HSV-2). Admedus Limited’s (ASX: AHZ) Herpes (HSV-2) vaccine Phase II study has received ethics approval to commence immediately. The study will investigate the safety and efficacy of the HSV-2 vaccine in patients with the Herpes virus. Genital herpes is an incurable sexually transmitted infection. Admedus, said they hoped to put the vaccine through a Phase II clinical study later this year.

Resources

Admedus Herpes Vaccine Phase 2

Admedus Limited (ASX: AHZ) will this month start vaccine dosing under its Herpes Simplex 2 (HSV-2) Phase II study with patient enrolment on track for completion this quarter. The company, now known under the name Admedus Vaccines, is researching DNA technology for vaccines with prophylactic and therapeutic potential. 4 million was posted as funds raised towards Phase II vaccine testing and research.

When Australian biotech Admedus announced Phase I results for its herpes simplex virus vaccine last week, it was far from the first company to do so. But there’s an important difference between this new crop of developers and those that have already struck out on an HSV-2 vaccine, Genocea CEO Chip Clark told FierceVaccines. Since that time several other potential vaccines being tested such as Admedus 2, Vical 3 and HSV-529 4. The vaccines must all go through phase II and phase III trials before being approved by the FDA, a process that typically takes at least 15 years.

Biotechs Angling For T-cell Response In Race For Next-gen Herpes Vaccine

The company had earlier this year received positive interim results for the therapeutic vaccine for Herpes Simplex Virus (HSV-2) Phase I study and is scheduled to release additional data this quarter once confirmatory assays are completed. Admedus’ (ASX: AHZ) final results from its Phase I Herpes Simplex Virus (HSV-2) vaccine study has showed that 95 (19 of 20) of the participants had a positive T-cell response when the trial reached is primary endpoint of safety. Admedus Limited’s Herpes vaccine Phase II study receives ethics approval.

Australia’s Admedus are boasting good results from early clinical trials of their version of the vaccine and Tomegavax, also in the States, is hot on the heals of a discovery with the support of the Bill and Melinda Gates foundation. All of the companies in the race are on phase II of their journeys and things are looking good so far with positive results being reported from all corners. In principle, there is no reason that a safe and effective HSV-2 vaccine could not be deployed in the human population to prevent HSV-2 genital herpes. What do you think about Admedus and Genocea vaccines? UL29, which is defective in HSV DNA replication, has been advanced to a Phase 1 study. Admedus (formally Coridon) to initiate phase II HSV-2 vaccine clinical trial before end 2014. There are (at my last count) 5 vaccine/therazine clinical trials going on. On top of that, Australian biotech Admedus just announced positive early clinical results for its own genital herpes vaccine. Big pharma dabbled in developing a genital herpes vaccine, but GlaxoSmithKline was particularly noteworthy for its epic flop compared to controls, it actually caused even worse outbreaks in the women studied in a huge Phase III study.

Herpes Vaccine Draws Nearer

Australian healthcare group Admedus released results on Thursday of the Phase 1 trial of Professor Frazer’s new vaccine to treat the herpes simplex virus HSV2. ‘We are looking forward to advancing our HSV-2 vaccine into a Phase II clinical study later this year but we will continue advancing our vaccines to treat Human Papillomavirus and cervical cancer. Admedus looking to initiate Phase II study for Herpes simplex virus (HSV-2) therapeutic vaccine by year end. Scientists created the vaccine HSV529 by removing two key proteins from the vaccine virus. In another trial conducted by Admedus, a diversified health company, the reality of a vaccine and a possible cure for the virus may be closer than you think. The initial phase of the clinical trial showed great results, which is leading them down the path of starting Phase 2. Admedus continues to advances the keenly awaited key Phase II HSV-2 study with the company anticipating interim results in the fourth quarter of 2015. Given that there is no cure available for HSV-2, which is a life-long infection, success will allow the company to tackle an unmet medical need with an addressable market estimated at 6 billion. Australian healthcare group Admedus released results last week of the Phase 1 trial of Professor Frazer’s new vaccine to treat the herpes simplex virus HSV2. We are looking forward to advancing our HSV-2 vaccine into a Phase II clinical study later this year but we will continue advancing our vaccines to treat Human Papillomavirus and cervical cancer. Admedus (ASX: AHX) has announced interim study results on its phase 1 trial of a therapeutic vaccine for herpes simplex virus (HSV-2). Admedus Limited’s (ASX: AHZ) Herpes (HSV-2) vaccine Phase II study has received ethics approval to commence immediately. The study will investigate the safety and efficacy of the HSV-2 vaccine in patients with the Herpes virus. Genital herpes is an incurable sexually transmitted infection. Admedus, said they hoped to put the vaccine through a Phase II clinical study later this year.

Resources

Real Time Web Analytics
Scroll To Top
Herpes Cure
Herpes Cure